PLANO, Texas, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical
device company, announced today the formation of the Nuvectra Medical Advisory Board (“MAB”). The Nuvectra MAB is composed of three
renowned experts in neurostimulation therapies and pain medicine. The MAB will serve as a key strategic resource for the Company as
it commercializes the Algovita® Spinal Cord Stimulation System. The MAB will help guide the development of clinical study and
marketing strategies, clinician education programs, and future pipeline initiatives.
The founding members of the Nuvectra MAB include:
- Robert M. Levy, MD, PhD, will serve as Chairman of the MAB. Dr. Levy is a board-certified neurological surgeon and is a
member of the Executive Board of Directors of the International Neuromodulation Society (“INS”). He has more than 25 years of
experience in neurosurgery, including serving in leadership and academic positions at prestigious institutions including
Northwestern University Medical School; University of Florida; and the Marcus Neuroscience Institute in Boca Raton, Florida. He
is also the Editor-in-Chief of Neuromodulation: Technology at the Neural Interface, the official journal of the INS.
- Jason E. Pope, MD, is board-certified in Anesthesiology and Pain Medicine. Dr. Pope previously served as faculty at
Vanderbilt University Medical Center and Cleveland Clinic. He is well published in peer-reviewed journals and has presented at
national and international conferences. He is the President of Summit Pain Alliance in Santa Rosa, CA, where he has an active
research group and continues to be highly engaged in national and international society work within the neuromodulation and pain
space.
- W. Porter McRoberts, MD, is board-certified in Physical Medicine and Rehabilitation (“PM&R”). He is a member of the Holy
Cross Hospital in Ft. Lauderdale, FL and is a thought leader amongst physicians who practice neurostimulation therapies. He has
been and currently is a principal investigator in numerous clinical trials studying medical device therapies for the treatment of
pain.
Dr. Levy commented, “The team at Nuvectra has developed a highly innovative neurostimulation platform that has
the potential to enhance clinical results and quality of life for patients receiving spinal cord stimulation. I look forward to
working with my fellow members of the Medical Advisory Board and collaborating with the Company to advance the clinical evidence of
the Algovita SCS system and other promising future applications.” Dr. Pope echoed a similar sentiment, “Nuvectra offers a
neurostimulation platform that may improve clinical outcomes and is well poised to be a leader in technology innovation for chronic
pain patients.”
Scott Drees, Chief Executive Officer of Nuvectra, said, “We are very pleased to introduce Drs. Levy, Pope and
McRoberts as the founding members of the Nuvectra Medical Advisory Board. As Chairman, Dr. Levy is uniquely positioned to lead the
Medical Advisory Board given his deep experience in the industry and position as Editor-in-Chief of Neuromodulation: Technology at
the Neural Interface, the official journal of International Neuromodulation Society. His experience provides him with a unique and
unparalleled perspective in neuromodulation therapies. We are also fortunate to have Dr. Pope and Dr. McRoberts on the Medical
Advisory Board; both are leaders in their respective fields of medicine and are actively involved in neurostimulation clinical
trials. All of these highly credentialed physicians will be instrumental in educating and training the medical community about the
clinical benefits of Algovita. The first objectives of the Nuvectra Medical Advisory Board will be focused on refining our post
market clinical study strategies for Algovita, with the goal of initiating the patient enrollment phase of these studies in the
near-future.”
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic
neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and
FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities
under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation
(DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the
neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements," including statements we make regarding the outlook
for Nuvectra as an independent publicly-traded company. Forward-looking statements are based only on our current beliefs,
expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions, and therefore they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and may be outside of our control. Our actual performance may differ materially from
those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any
forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which
it is made. Important factors that could cause our actual results to differ materially from those indicated in the
forward-looking statements include: (i) our ability to successfully commercialize Algovita and to develop, complete and
commercialize enhancements or improvements to Algovita; (ii) our ability to successfully compete with our current SCS competitors
and the ability of our U.S. sales representatives to successfully establish market share and acceptance of Algovita, (iii) our
ability to demonstrate the features, perceived benefits and capabilities of Algovita to physicians and patients in competition with
similar products already well established and sold in the SCS market; (iv) our ability to anticipate and satisfy customer needs and
preferences and to develop, introduce and commercialize new products or advancements and improvements to Algovita in order to
successfully meet our customers’ expectations; (v) the outcome of our development plans for our neurostimulation technology
platform, including our ability to identify additional indications or conditions for which we may develop neurostimulation medical
devices or therapies and seek regulatory approval thereof; (vi) our ability to identify business development and growth
opportunities and to successfully execute on our strategy, including our ability to seek and develop strategic partnerships with
third parties to, among other things, fund clinical and development costs for new product offerings; (vii) the performance by our
development partners, including Aleva Neurotherapeutics, S.A., of their obligations under their agreements with us; (viii) the
scope of protection for our intellectual property rights covering Algovita and other products using our neurostimulation technology
platform, along with any product enhancements or improvements; (ix) our ability to successfully build, attract and maintain an
effective commercial infrastructure and qualified sales force in the United States; (x) our compliance with all regulatory and
legal requirements regarding implantable medical devices and interactions with healthcare professionals; and (xi) any product
recalls, or the receipt of any warning letters, mandatory corrections or fines from any governmental or regulatory agency.
Please see the sections entitled “Cautionary Statement Concerning Forward-Looking Statements" and “Risk Factors” in Nuvectra’s
Registration Statement on Form 10 and in our other quarterly and periodic filings for a description of these and other risks and
uncertainties. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may
be made from time to time, whether as a result of new information, future developments or otherwise.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Financial Officer (214) 474-3102 wberger@nuvectramed.com Jennifer Armstrong, Media Relations (214) 474-3110 jarmstrong@nuvectramed.com Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 nlaudico@theruthgroup.com Zack Kubow (646) 536-7020 zkubow@theruthgroup.com
